A retrospective study based on FAERS database highlighted the incidence and severity of neutropenia, identifying fever and neutropenia as common fatal adverse events in PD-L1 monotherapy and the most prevalent fatal adverse events in PD-L1 combined with bevacizumab (83). This evidence concerns the gene CD274 and neutropenia.